We investigated the use of statins in clinical practice in patients with ac
ute myocardial infarction in Germany in 17732 consecutively included patien
ts of the registries MIR-1 and MITRA-1. A clinical follow-up has been perfo
rmed in the MITRA-1 study after a mean period of 18 months. In total 30% of
all patients with acute myocardial infarction received statins at discharg
e. From 1994 to 1998 the use of statins increased from 6% to 44%; however i
n 1998 still less than half of the patients with acute myocardial infarctio
n received statins at discharge. In a logistic regression model, concomitta
nt diseases as renal failure (OR 0.7), heart failure (OR 0.7) and diabetes
mellitus (OR 0.9) were associated with a lower use of statins. Age > 70 yea
rs (OR 0.5) was also associated with a lower use of statins at hospital dis
charge. Patients with statins at discharge had a lower long-term mortality
of 5.8% versus 12.9% in patients without statins. After adjustment to age a
nd comorbidity, use of statins at discharge was associated with a borderlin
e significant reduction of long-term mortality (multivariate OR 0.7, 95% CI
0.4-1.0). In a subgroup analysis of therapeutic benefit, measured by the "
number needed to treat" (NNT), the number of patients to treat with statins
to save one life, patients with cardiovascular risk factors, as heart fail
ure (NNT 7.5), diabetes mellitus (NNT 7.8) and age > 70 years (NNT 13.8) ha
d a larger therapeutic benefit as patients without these risk factors (NNT
345). However, these high-risk patients received less often statins than pa
tients without risk factors (use of statins 11.8% versus 19.8%).